SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (1960)3/28/2002 12:33:57 PM
From: Harold Engstrom  Respond to of 10345
 
Yes. You are right. I confess I do not pay attention much to posturing with respect to unnamed future partners (I always assume it is all bs, so in general I am a tough one to disappoint.)



To: William Partmann who wrote (1960)3/29/2002 9:32:13 AM
From: arnie h  Respond to of 10345
 
Bill: At $13 a share for ELN, UCB seems major to me. At $50 I would have defined it differently.
More to the point is whether the world needs a migraine drug with a long half life. If it does for some, this could turn out well as many docs tend to use a drug that works for more people even if the prior alternatives work for almost as many. Example is Lipitor.
Arnie


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News